2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Julie Lemieux, MD, MSc, presenting abstract LBA506, Patient reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer during Breast Cancer? HER2/ER Oral Abstract Session

Julie Lemieux, MD, MSc, presenting abstract LBA506, Patient reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer during Breast Cancer? HER2/ER Oral Abstract Session

Chicago, IL - 2016 ASCO Annual Meeting - Julie Lemieux, MD, MSc, presenting abstract LBA506, Patient reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer during Breast Cancer? HER2/ER Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Monday, June 6, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Max Gersh 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org